ALX Oncology Holdings Inc.
ALXOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Feb 5, 2026 | Piper Sandler | $4.00(+99%) | $2.01 | TheFly | |
| Mar 7, 2025 | Stifel Nicolaus | $1.50(+42%) | $1.06 | TheFly | |
| Jun 10, 2024 | UBS | Colin Bristow | $25.00(+183%) | $8.82 | StreetInsider |
| Jun 3, 2024 | Raymond James | Christopher Raymond | $21.00(+131%) | $9.10 | StreetInsider |
| Apr 10, 2024 | Stifel Nicolaus | Bradley Canino | $14.00(+18%) | $11.85 | StreetInsider |
| Aug 9, 2022 | Credit Suisse | $38.00(+223%) | $11.77 | Benzinga | |
| Jun 13, 2022 | Stifel Nicolaus | Bradley Canino | $16.00(+136%) | $6.79 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Mar 10, 2026 |
| Piper Sandler | maintain | Overweight | Feb 5, 2026 |
| UBS | maintain | Buy | May 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2025 |
| Stifel | maintain | Hold | Mar 7, 2025 |
| Piper Sandler | maintain | Overweight | Mar 6, 2025 |
| Jefferies | upgrade | Hold →Buy | Mar 6, 2025 |
| UBS | maintain | Buy | Jan 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 24, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Jan 24, 2025 |
| Jefferies | downgrade | Buy →Hold | Dec 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 18, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Dec 18, 2024 |
| UBS | maintain | Buy | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2024 |
| Stifel | maintain | Hold | Aug 9, 2024 |
| Stifel | maintain | Hold | Aug 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2024 |
| Stifel | downgrade | Buy →Hold | Mar 8, 2024 |
| Piper Sandler | maintain | Overweight | Mar 8, 2024 |
| Jefferies | upgrade | Hold →Buy | Dec 8, 2023 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.13| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.13 | $-0.14 | — | — |
| May 8, 2026 | $-0.17 | $-0.15 | — | — |
| Feb 27, 2026 | $-0.42 | $-0.38 | — | — |
| Nov 7, 2025 | $-0.41 | $-0.37 | — | — |
| Aug 12, 2025 | $-0.49 | $-0.46 | — | — |
| May 8, 2025 | $-0.58 | $-0.47 | — | — |
| Mar 6, 2025 | $-0.55 | $-0.72 | — | — |
| Nov 7, 2024 | $-0.58 | $-0.78 | — | — |
News
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
BlackRock Inc. bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,399,530 shares of the company's stock, valued at approximately $15,317,000. BlackRock Inc. owned 5.50% of ALX Oncology
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,057,325 shares of the company's stock, valued at approximately $6,328,663,000. ALX Oncology makes up
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.